Neurogene (NGNE) Stock
Clinical stage biotech designing custom immune proteins. Here's the price, business snapshot, and what's worth knowing about Neurogene in November 2026.
Neoleukin Therapeutics, Inc. (NGNE) is a clinical‑stage biotechnology company focused on designing de novo protein therapeutics intended to modulate the immune system. The firm engineers novel protein scaffolds that mimic natural cytokines with the aim of improving anti‑cancer immune responses while reducing side effects seen with native molecules. As a small‑cap company (market capitalisation around $450.6M), Neoleukin’s value is driven largely by early clinical data, regulatory progress and partnerships rather than steady revenue. Investing in such companies involves binary outcomes — positive trial results can materially increase value, while setbacks or funding challenges can lead to sharp declines. Investors should monitor trial updates, cash runway disclosed in SEC filings, and scientific readouts, and be aware this is high‑risk, speculative exposure. This is educational information and not personalised investment advice; suitability depends on your risk tolerance and portfolio goals.
Neurogene (NGNE) Stock Forecast
Analyst price target, next 12 months
$69.22
+162.6% vs today's $26.36
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Neurogene have a consensus 12-month target of $69.22, above the current price of $26.36.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 6 Nov 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Neurogene's stock, expecting its price to rise significantly.
Financial Health
Neurogene is showing strong financial performance with good cash flow and asset value.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
De novo protein design
Neoleukin’s engineered proteins aim to replicate immune signalling with potential safety benefits, though clinical proof is still evolving and outcomes are uncertain.
Data‑driven moves
Share direction often follows clinical readouts and regulatory news; trial results can create sharp moves in either direction.
Watch funding and partners
Cash runway and collaborations shape long‑term prospects; small‑cap biotech financing needs can dilute shareholders if additional capital is required.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
